CAR-TCR European Summit Round-Up: Cellectis-Cytovia Partnership; JNJ’s (Janssen) Thoughts on EU CAR-T Reimbursement; Strategies to Improve CAR-T Fitness

During the CAR-TCR European Summit 2021, eight key CAR-T related topics were observed. Six updates covering Cellectis, JNJ (Janssen), Dorian Therapeutics, Antion Biosciences, Prescient Therapeutics, and Avectas are summarized below. Of note, no major clinical updates were presented by Precision BioSciences or Gilead (Kite). Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.